Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin
Recruiting
Phase 2
Interventional Study
Cancer (Solid Tumors)
Vomiting
Cisplatin
Olanzapine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 95 (estimated)
- Sponsor
- Mahidol University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* histologically confirmed solid malignancy
* scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2
Exclusion Criteria:
* pregnancy
* pelvic or abdominal radiation within 4 weeks
* uncontrolled brain metastasis
* other moderate or high emetic risk chemotherapy …
Contacts